Papillary thyroid cancer (PTC) has an exceptional favorable prognosis, with a 20-year overall survival rate exceeding 90%, even reaching 95% for papillary thyroid microcarcinoma. This excellent prognosis has prompted the exploration of more conservative management strategies beyond surgery, such as active surveillance and thermal ablation. The cosmetic benefits and less invasive nature of thermal ablation make it a recommended treatment for benign thyroid nodules, but its use in treating PTC is still in the experimental phase.